Sale

Monoclonal Antibodies Market

Global Monoclonal Antibodies Market Size, Growth, Trends: By Production Type: In Vitro, In Vivo; By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, Other; By End User: Hospitals, Specialty Clinics, Others; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032

Global Monoclonal Antibodies Market Outlook

The global monoclonal antibodies market size was valued at USD 210.6 billion in 2023, driven by the rising prevalence of chronic and infectious diseases across the globe. The market is expected to grow at a CAGR of 11.5% during the forecast period of 2024-2032, with the values likely to rise from USD 234.9 billion in 2024 to USD 562.8 billion by 2032.

 

Global Monoclonal Antibodies Market Overview

Monoclonal antibodies have therapeutic potential as they carry the ability to enhance, restore, modify, or mimic the immune system’s attack on certain unwanted cells, like cancer cells. They are a form of targeted drug therapy that is administrated intravenously. The rising prevalence of chronic diseases and infectious diseases drives the need for effective monoclonal antibody therapies to treat various medical conditions.

 

The global burden of chronic diseases is rapidly increasing which is expected to bolster the monoclonal antibodies market growth in coming years. According to the World Health Organisation (WHO), chronic diseases account for 41 million deaths annually. It is further estimated that cancer and diabetes cause 9.3 million and 2 million deaths per year, respectively.  Monoclonal antibodies, with their ability to target disease mechanisms, can offer a promising treatment solution to combat these rising cases of global mortality due to chronic disease.

 

The market is witnessing increased strategic partnerships, collaborations, and research and development (R&D) investments from various public and private organizations. In September 2023, the United States Department of Health and Human Services (HHS) announced an extension of its partnership with Regeneron Pharmaceuticals.  The agreement, valued at USD 326 million, is expected to support the development of a next-generation monoclonal antibody for COVID-19 prevention and is a part of HHS’s Project NextGen. The contract states that the list price of the new product if commercialized, should either be equivalent to or lesser than its approved price in comparable markets globally. Such public-private partnerships are anticipated to greatly impact the monoclonal antibodies market size in the forecast period.

 

Other factors that influence the market dynamics include the growing adoption of monoclonal antibody therapies in the healthcare sector, heightened patient awareness, and improvements in the regulatory landscape which enables the availability of new therapeutic options in the markets. Moreover, the rise in research initiatives aimed at developing innovative monoclonal antibody therapies is likely to augment the market size.

 

Global Monoclonal Antibodies Market Trends 

Key Trend Impact
Rapid Technological Advancements Technological advancements in biotechnology and genetic engineering have fuelled the development as well as the production of monoclonal antibodies (mAbs). Innovations like recombinant DNA technology, hybridoma technology, and phage display have improved the specificity and efficacy of monoclonal antibodies against their targets. This trend expands monoclonal antibody applications across a wide range of diseases, including cancer, autoimmune diseases, and infectious diseases, and helps in attracting significant research and development investment.
Growing Demand for Personalized Medicine The growing demand for personalized medicine and the increasing emphasis on understanding the genetic basis of diseases have made a significant impact on the market. Monoclonal antibody therapies can be tailored to individual patient profiles, based on genetic markers and disease characteristics. Such customization opportunities can improve treatment outcomes and reduce side effects, driving the monoclonal antibodies market demand to facilitate a targeted approach in therapy development.
Improvements in Regulatory Framework     Supportive regulatory environments such as fast-track designations, orphan drug status, and breakthrough therapy designations, have greatly impacted the market. Such regulatory reforms accelerate the approval process for promising monoclonal antibody therapies. This also encourages pharmaceutical companies to invest in the development of monoclonal antibodies for unmet medical needs of patients across the world. Moreover, the evolving regulatory framework speeds up the availability of innovative treatments to patients.
Expansion into Emerging Markets The rising healthcare expenditures, improving healthcare infrastructure, and growing public awareness of advanced therapies have accelerated the expansion of the monoclonal antibodies market share into emerging economies. These emerging markets offer potential for monoclonal antibodies due to their large patient populations and increasing incidence of diseases treatable by the therapeutic. Further, key market players are strategically entering these markets, thus driving market growth and accessibility to monoclonal antibodies therapies.

 

Global Monoclonal Antibodies Market Segmentation

Market Breakup by Production Type

  • In Vitro
  • In Vivo

 

The market segmentation by production includes in vitro and in vivo production methods. This market segment illustrates the different approaches utilized to produce monoclonal antibodies.

 

Market Breakup by Application

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Diseases
  • Other

 

Monoclonal antibodies are utilized in various therapeutic areas including oncology, autoimmune diseases, infectious diseases, neurological diseases, and others, addressing a wide range of medical conditions. The applications of monoclonal antibodies are rapidly expanding to treat a range of chronic and infectious diseases. This increased use is expected to augment the market scope and elevate monoclonal antibodies market value.

 

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Others

 

End-users of monoclonal antibodies include hospitals, and specialty clinics, among others. These healthcare facilities provide access to these biologic agents for diverse patient populations and clinical needs.

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

The monoclonal antibodies market analysis offers insights into major regional markets such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads the market segment which can be attributed to the presence of an advanced healthcare infrastructure along with heightened patient awareness which enables more people to seek monoclonal antibody treatment options. Further, the rise in the prevalence of chronic diseases, with recent data suggesting that 6 in 10 Americans are affected by at least 1 chronic disease , directly impacts the market demand in the region.

 

Global Monoclonal Antibodies Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • Merck & Co. Inc
  • Daiichi Sankyo Company, Limited
  • Abbott Laboratories
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Johnson & Johnson
  • Bristol Myers Squibb
  • F. Hoffmann La Roche Ltd.
  • Biogen Inc.
  • Sanofi
  • Novo Nordisk A/S

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Production Type
  • Application
  • End User
  • Region
Breakup by Production Type
  • In Vitro 
  • In Vivo
Breakup by Application
  • Oncology 
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Diseases 
  • Other
Breakup by End User
  • Hospitals 
  • Specialty Clinics 
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Novartis AG 
  • Pfizer Inc. 
  • GlaxoSmithKline PLC 
  • Merck & Co. Inc 
  • Daiichi Sankyo Company, Limited 
  • Abbott Laboratories
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Johnson & Johnson 
  • Bristol Myers Squibb 
  • F. Hoffmann La Roche Ltd. 
  • Biogen Inc.
  • Sanofi 
  • Novo Nordisk A/S  

 

Key Queries Solved in the Global Monoclonal Antibodies Market Report

  • How will the market landscape evolve in the forecast period? 
  • What future trends can be anticipated in the market?
  • What will be the effect of each driver, challenge, and opportunity on the market? 
  • Which regional market is expected to experience expedited growth during the forecast period? 
  • Which production type will lead the market growth? 
  • Which end user is expected to dominate the respective market segment? 
  • What are the key research initiatives expected to boost the market value during the forecast period? 
  • Which application is poised to make the highest impact on the monoclonal antibodies market growth? 
  • What are the market shares, strategies, and product portfolios of the leading players in the market?
  • How is the regulatory landscape shaping the market?
  • What are the market dynamics, trends, and growth prospects in the key regional markets?
  • How is technology innovation impacting the development of monoclonal antibodies?
  • What are the investment opportunities and potential risks associated with the market?

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Monoclonal Antibodies Market Overview 

    3.1    Global Monoclonal Antibodies Market Historical Value (2017-2023) 
    3.2    Global Monoclonal Antibodies Market Forecast Value (2024-2032)
4    Global Monoclonal Antibodies Market Landscape*
    4.1    Global Monoclonal Antibodies: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Monoclonal Antibodies: Product Landscape
        4.2.1    Analysis by Production Type        
        4.2.2    Analysis by Application
5    Global Monoclonal Antibodies Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Global Monoclonal Antibodies Market Segmentation (2017-2032)
    6.1    Global Monoclonal Antibodies Market (2017-2032) by Production Type
        6.1.1    Market Overview    
        6.1.2    In Vitro 
        6.1.3    In Vivo
    6.2    Global Monoclonal Antibodies Market (2017-2032) by Application
        6.2.1    Market Overview    
        6.2.2    Oncology 
        6.2.3    Autoimmune Diseases
        6.2.4    Infectious Diseases
        6.2.5    Neurological Diseases 
        6.2.6    Other
    6.3    Global Monoclonal Antibodies Market (2017-2032) by End User
        6.3.1    Market Overview    
        6.3.2    Hospitals 
        6.3.3    Specialty Clinics 
        6.3.4    Others
    6.4    Global Monoclonal Antibodies Market (2017-2032) by Region
        6.4.1    Market Overview
        6.4.2    North America
        6.4.3    Europe 
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America Monoclonal Antibodies Market (2017-2032)
    7.1    North America Monoclonal Antibodies Market (2017-2032) by Production Type
        7.1.1    Market Overview    
        7.1.2    In Vitro 
        7.1.3    In Vivo
    7.2    North America Monoclonal Antibodies Market (2017-2032) by Application
        7.2.1    Market Overview    
        7.2.2    Oncology 
        7.2.3    Autoimmune Diseases
        7.2.4    Infectious Diseases
        7.2.5    Neurological Diseases 
        7.2.6    Other
    7.3    North America Monoclonal Antibodies Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Monoclonal Antibodies Market (2017-2032)
    8.1    Europe Monoclonal Antibodies Market (2017-2032) by Production Type
        8.1.1    Market Overview    
        8.1.2    In Vitro 
        8.1.3    In Vivo
    8.2    Europe Monoclonal Antibodies Market (2017-2032) by Application
        8.2.1    Market Overview    
        8.2.2    Oncology 
        8.2.3    Autoimmune Diseases
        8.2.4    Infectious Diseases
        8.2.5    Neurological Diseases 
        8.2.6    Other
    8.3    Europe Monoclonal Antibodies Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Monoclonal Antibodies Market (2017-2032)
    9.1    Asia Pacific Monoclonal Antibodies Market (2017-2032) by Production Type
        9.1.1    Market Overview    
        9.1.2    In Vitro 
        9.1.3    In Vivo
    9.2    Asia Pacific Monoclonal Antibodies Market (2017-2032) by Application
        9.2.1    Market Overview    
        9.2.2    Oncology 
        9.2.3    Autoimmune Diseases
        9.2.4    Infectious Diseases
        9.2.5    Neurological Diseases 
        9.2.6    Other
    9.3    Asia Pacific Monoclonal Antibodies Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America  Monoclonal Antibodies Market (2017-2032)
    10.1     Latin America Monoclonal Antibodies Market (2017-2032) by Production Type
        10.1.1    Market Overview    
        10.1.2    In Vitro 
        10.1.3    In Vivo
    10.2    Latin America Monoclonal Antibodies Market (2017-2032) by Application
        10.2.1    Market Overview    
        10.2.2    Oncology 
        10.2.3    Autoimmune Diseases
        10.2.4    Infectious Diseases
        10.2.5    Neurological Diseases 
        10.2.6    Other
    10.3    Latin America Monoclonal Antibodies Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa Monoclonal Antibodies Market (2017-2032)
    11.1     Middle East and Africa Monoclonal Antibodies Market (2017-2032) by Production Type
        11.1.1    Market Overview    
        11.1.2    In Vitro 
        11.1.3    In Vivo
    11.2    Middle East and Africa Monoclonal Antibodies Market (2017-2032) by Application
        11.2.1    Market Overview    
        11.2.2    Oncology 
        11.2.3    Autoimmune Diseases
        11.2.4    Infectious Diseases
        11.2.5    Neurological Diseases 
        11.2.6    Other
    11.3     Middle East and Africa Monoclonal Antibodies Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
    12.1    Regulatory Overview 
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    JAPAN PMDA
        12.1.4    Others
13    Patent Analysis
    13.1     Analysis by Type of Patent
    13.2     Analysis by Publication year
    13.3     Analysis by Issuing Authority
    13.4     Analysis by Patent Age
    13.5     Analysis by CPC Analysis
    13.6     Analysis by Patent Valuation 
    13.7     Analysis by Key Players
14    Grants Analysis
    14.1     Analysis by Year
    14.2     Analysis by Amount Awarded
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Grant Application
    14.5     Analysis by Funding Institute
    14.6     Analysis by Departments
    14.7     Analysis by Recipient Organization 
15    Clinical Trials Analysis
    15.1     Analysis by Trial Registration Year
    15.2    Analysis by Trial Status
    15.3    Analysis by Trial Phase
    15.4    Analysis by Therapeutic Area 
    15.5    Analysis by Geography
16    Funding and Investment Analysis
    16.1     Analysis by Funding Instances
    16.2     Analysis by Type of Funding
    16.3     Analysis by Funding Amount
    16.4     Analysis by Leading Players
    16.5     Analysis by Leading Investors
    16.6     Analysis by Geography
17    Partnership and Collaborations Analysis
    17.1     Analysis by Partnership Instances
    17.2     Analysis by Type of Partnership
    17.3     Analysis by Leading Players
    17.4     Analysis by Geography
18    Supplier Landscape
    18.1     Novartis AG 
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Pfizer Inc. 
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    GlaxoSmithKline PLC 
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Merck & Co. Inc 
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Daiichi Sankyo Company, Limited 
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Abbott Laboratories 
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    AstraZeneca PLC 
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Eli Lilly and Company
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Johnson & Johnson 
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Bristol Myers Squibb 
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    F. Hoffmann La Roche Ltd. 
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    Biogen Inc. 
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Sanofi 
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    Novo Nordisk A/S  
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions 
        18.14.5    Certifications
19    Global  Monoclonal Antibodies Market – Distribution Model (Additional Insight)
    19.1     Overview 
    19.2     Potential Distributors 
    19.3     Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1     Very Small Companies
    21.2     Small Companies
    21.3     Mid-Sized Companies
    21.4     Large Companies
    21.5     Very Large Companies
22    Payment Methods (Additional Insight)
    22.1     Government Funded
    22.2     Private Insurance
    22.3     Out-of-Pocket
    

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

The market attained a value of about USD 210.6 billion in 2023 driven by the rising prevalence of chronic and infectious diseases.

The market is anticipated to grow at a CAGR of 11.5% during the forecast period of 2024-2032, likely to reach a market value of USD 562.8 billion by 2032.

Heightened patient awareness and increased healthcare expenditure are fuelling the demand for the market.

One of the significant trends in the market is increased strategic partnerships, collaborations, and research and development investments from various public and private organizations. In September 2023, the United States Department of Health, and Human Services (HHS) announced its partnership extension with Regeneron Pharmaceuticals. Valued at USD 326 million, the agreement is anticipated to support the development of a next-generation monoclonal antibody for COVID-19 prevention.

Based on the production type, the market is segmented into in vitro and in vivo production methods.

End-users of monoclonal antibodies include hospitals, and specialty clinics, among others.

Applications of monoclonal antibodies include oncology, autoimmune diseases, infectious diseases, neurological diseases, and others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

Key players involved in the market are Novartis AG, Pfizer Inc., GlaxoSmithKline PLC, Merck & Co. Inc, Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Johnson & Johnson, Bristol Myers Squibb, F. Hoffmann La Roche Ltd., Biogen Inc., Sanofi, and Novo Nordisk A/S.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER